London
· Delayed Price · Currency is GBP · Price in EUR ABIONYX Pharma Statistics
Total Valuation
ABIONYX Pharma has a market cap or net worth of GBP 36.25 million. The enterprise value is 34.46 million.
| Market Cap | 36.25M |
| Enterprise Value | 34.46M |
Important Dates
The next estimated earnings date is Thursday, March 6, 2025.
| Earnings Date | Mar 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +11.19% |
| Shares Change (QoQ) | +7.17% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 17.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 10.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.11 |
| EV / Sales | 8.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -13.15 |
Financial Position
The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.34.
| Current Ratio | 2.28 |
| Quick Ratio | 2.17 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.03 |
| Interest Coverage | -122.52 |
Financial Efficiency
Return on equity (ROE) is -47.16% and return on invested capital (ROIC) is -19.04%.
| Return on Equity (ROE) | -47.16% |
| Return on Assets (ROA) | -14.12% |
| Return on Invested Capital (ROIC) | -19.04% |
| Return on Capital Employed (ROCE) | -27.22% |
| Revenue Per Employee | 67,492 |
| Profits Per Employee | -46,672 |
| Employee Count | 61 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 21.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.25% in the last 52 weeks. The beta is 0.29, so ABIONYX Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | +3.25% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 1.28 |
| Relative Strength Index (RSI) | 44.95 |
| Average Volume (20 Days) | 557 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ABIONYX Pharma had revenue of GBP 4.12 million and -2.85 million in losses. Loss per share was -0.09.
| Revenue | 4.12M |
| Gross Profit | 790,168 |
| Operating Income | -2.80M |
| Pretax Income | -2.85M |
| Net Income | -2.85M |
| EBITDA | -2.70M |
| EBIT | -2.80M |
| Loss Per Share | -0.09 |
Balance Sheet
The company has 4.50 million in cash and 2.69 million in debt, giving a net cash position of 1.81 million.
| Cash & Cash Equivalents | 4.50M |
| Total Debt | 2.69M |
| Net Cash | 1.81M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 8.01M |
| Book Value Per Share | 0.25 |
| Working Capital | 3.60M |
Cash Flow
In the last 12 months, operating cash flow was -2.57 million and capital expenditures -50,021, giving a free cash flow of -2.62 million.
| Operating Cash Flow | -2.57M |
| Capital Expenditures | -50,021 |
| Free Cash Flow | -2.62M |
| FCF Per Share | n/a |
Margins
Gross margin is 19.19%, with operating and profit margins of -68.12% and -69.15%.
| Gross Margin | 19.19% |
| Operating Margin | -68.12% |
| Pretax Margin | -69.15% |
| Profit Margin | -69.15% |
| EBITDA Margin | -65.65% |
| EBIT Margin | -68.12% |
| FCF Margin | n/a |
Dividends & Yields
ABIONYX Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.19% |
| Shareholder Yield | -11.19% |
| Earnings Yield | -7.85% |
| FCF Yield | -7.23% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ABIONYX Pharma has an Altman Z-Score of 3.42.
| Altman Z-Score | 3.42 |
| Piotroski F-Score | n/a |